Akums Drugs & Pharmaceuticals Ltd.
Akums Drugs & Pharmaceuticals Ltd. Fundamental Analysis
Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS) shows weak financial fundamentals with a PE ratio of 25.23, profit margin of 7.56%, and ROE of 10.27%. The company generates $42.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze AKUMS.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakAKUMS.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakAKUMS.NS trades at a premium to fair value.
Growth Score
ModerateAKUMS.NS shows steady but slowing expansion.
Financial Health Score
ExcellentAKUMS.NS maintains a strong and stable balance sheet.
Profitability Score
WeakAKUMS.NS struggles to sustain strong margins.
Key Financial Metrics
Is AKUMS.NS Expensive or Cheap?
P/E Ratio
AKUMS.NS trades at 25.23 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, AKUMS.NS's PEG of 75.08 indicates potential overvaluation.
Price to Book
The market values Akums Drugs & Pharmaceuticals Ltd. at 2.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.22 times EBITDA. This signals the market has high growth expectations.
How Well Does AKUMS.NS Make Money?
Net Profit Margin
For every $100 in sales, Akums Drugs & Pharmaceuticals Ltd. keeps $7.56 as profit after all expenses.
Operating Margin
Core operations generate 7.44 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.27 in profit for every $100 of shareholder equity.
ROA
Akums Drugs & Pharmaceuticals Ltd. generates $6.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Akums Drugs & Pharmaceuticals Ltd. generates strong operating cash flow of $15.47B, reflecting robust business health.
Free Cash Flow
Akums Drugs & Pharmaceuticals Ltd. generates strong free cash flow of $13.13B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $85.73 in free cash annually.
FCF Yield
AKUMS.NS converts 16.35% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.23
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
75.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.91
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.95
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How AKUMS.NS Stacks Against Its Sector Peers
| Metric | AKUMS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.23 | 28.96 | Better (Cheaper) |
| ROE | 10.27% | 716.00% | Weak |
| Net Margin | 7.56% | -46137.00% (disorted) | Weak |
| Debt/Equity | 0.03 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 3.95 | 4.52 | Strong Liquidity |
| ROA | 6.17% | -17407.00% (disorted) | Weak |
AKUMS.NS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Akums Drugs & Pharmaceuticals Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation